As a bio big data-based biopharmaceutical company that develops global innovative new drugs for diseases without therapeutic alternatives worldwide, such as degenerative disc, degenerative arthritis, TNBC, Alzheimer’s disease and type 1 diabetes, Ensol Biosciences applies bio big data-based BT/IT convergence technology from the aspects of drug efficacy, mechanism and toxicity, and side effects to develop outstanding drugs with high potential, and works on various discoveries and clinical trial phases systematically.

KISDD 3.0 is a unique knowledge-based in silico drug discovery platform for screening new drug candidates for the treatment of a disease. The platform establishes drug discovery strategy through the holistic understanding of diseases. It uses huge amount of databases, profound knowledge information and high-performance computing technology to find out effective drug candidates. When drug candidates are found by the platform, we first confirm the efficacy and identify the mechanism of action. And then we conduct biological experiments necessary for the development of a new drug. ETONS is shows how all kinds of protein, genes and metabolites in human body (or animal, plant, microorganism) interact with each other in the form of a gigantic 3-dimensional network. ETONS analyzes massive literature data through machine-learning (a kind of artificial intelligence) and uses text-mining technology to turn it in to data base. ETONS can receive omics data and help with the overall new drug development, from the target investigation, mechanism investigation to prediction of side effects.

Public

Biotech